7:45 AM - 8:45 AM
Registration & Breakfast
8:45 AM - 9:00 AM
Chairman’s Opening Remarks
Smart Pharma: Key Trends That Will Enable The Reshaping of Drug Discovery and Development
General Partner
New Ventures Funds
9:00 AM - 9:40 AM
Executive Viewpoints: Will AI Be Innovation or Renovation for Biopharma?
Chief Data Officer
VL49 - a Flagship Pioneering Company
9:40 AM - 10:05 AM
Internal Collaboration: Moving Toward the Value of End-to-End Maching Learning for Pipeline Optimization
10:05 AM - 10:30 AM
The Handbook on how to Find the Right External Partners
10:30 AM - 10:55 AM
Early Stage R&D Use Cases
10:55 AM - 11:25 AM
Networking, Refreshments & Expert One-to-One Meetings
11:25 AM - 11:50 AM
Late Stage R&D Use Cases
11:50 AM - 12:15 PM
Employing AI to find the Translational Piece for Making Drugs Effective, Validated and Useful in Humans
12:15 PM - 1:15 PM
Networking Lunch & Expert One-to-One Meetings
1:15 PM - 1:40 PM
Using Deep Learning to Improve Drug Development Success Outcomes
This session will look at how AI technology such as Deep Learning is being applied to the challenge of drug failure, both in discovery and in clinical trials. One of the primary drivers of R&D expense is the high number of failures that occur during the development of a therapeutic. Many pharmaceutical companies are now looking at AI solutions to better predict which assets will succeed in trials, and to design compounds have been optimized for success. Some specific examples:
- Using clinical trial outcomes to improve estimates of success.
- Currently approximately 50% of trials fail due to ADME/Tox issues – examples of how Pfizer is using
- DL to help change this.
- How is medicinal chemistry and design changing with AI?
- Using AI earlier in the discovery cycle to select targets and indications for investment.
Director, World Wide R&D Strategy
Pfizer
1:40 PM - 2:05 PM
Virtual Trials
2:05 PM - 2:35 PM
Getting to the Proof of Innovation: Case Studies From AI Use in Clinical Trials
2:35 PM - 3:05 PM
Afternoon Refreshments & Expert One-to-One Meetings
3:05 PM - 3:55 PM
Clinical Development
Speakers
Global Head Digital Trials- Global Clinical Operations
Boehringer Ingelheim Pharmaceuticals, Inc.
Data Democratization & Interopability
4:00 PM - 4:25 PM
An AI Powered Project: Human Genetics & Drug Discovery
4:25 PM - 5:00 PM
Innovation Spotlight Changemaker Presentations
Moderator
President & CEO Massachusetts Life Sciences Center
Changemaker Presenter
Founder & President
Data2Discovery Inc
5:00 PM - 6:00 PM
Evening Reception
8:00 AM - 9:00 AM
Breakfast & Expert One-to-One Meetings
9:00 AM - 9:25 AM
Overcoming Barriers to RWE Adoption and Realizing Value
Global Head, Real World Evidence Strategy
Biogen
9:25 AM - 9:50 AM
Innovate Practically: Finding the Intersections Between AI and RWE to Better Treat Patients
Vice President, Head of Real World Data and Analytics Center of Excellence
Pfizer
9:50 AM - 10:15 AM
FDA Update on Using RWE
10:15 AM - 10:40 AM
Data Diversity and Access: Impacting Patients in Meaningful Ways and Avoiding Data Biases
Senior Director, US R&D Policy & Scientific Affairs, R&D Strategy, Portfolio & Operations
GSK
10:40 AM - 11:10 AM
Morning Refreshments & Expert One-to-One Meetings
11:10 AM - 11:35 AM
Data Organization and Communication: Unlocking the Value of Insights
This session features two case study presentations that will address the importance of data organization across an organization to unlock the value of the data being collected.
• Why one-size-fits-all systems don’t work (at least right now).
• Janssen’s “ecosystem of platforms” approach to taking existing systems for different purposes and integrating them for better data access
• Methods for capturing data sets to do analysis across the company instead of in silos.
• A view into current Janssen projects.
VP of Data Science, Oncology
The Janssen Pharmaceutical Companies of Johnson & Johnson
11:35 AM - 12:00 PM
Creating Strong Staffing and Culture Models to Effectively Produce Transformative Therapies Faster
12:00 PM - 12:40 PM
Open Discussion: New Collaborative Models to Impact Patients in More Meaningful Ways
12:40 PM - 12:45 PM
Chair's Closing Remarks